Original reporting and analysis on the stories shaping biotech.
The FDA approved a needle-free alternative to the EpiPen over a year ago. But CVS Caremark just punted its formulary decision again, leaving millions of allergy patients stuck navigating a maze of prior authorizations and denials for a nasal spray that could save their lives.
BIO 2026 wasn't the usual deal-making party. This year's conference surfaced three strategic tensions reshaping biotech: the messy reality of decoupling from China, the Biosecure Act's slow-rolling disruption, and AI drug discovery's biggest deal yet.
iBio, a company that used to grow antibodies in tobacco plants, just dosed the first patient with an AI-designed obesity drug that took only seven months to discover. It's a wild pivot into the most competitive drug market on Earth.
For the first time in any clinical trial, patients with FSHD gained muscle mass instead of losing it. Epicrispr's one-shot epigenetic therapy just delivered a result that no drug has ever achieved in this devastating muscular dystrophy.
Viridian Therapeutics just scored FDA approval for Lumvoa four days ahead of schedule, giving thyroid eye disease patients a faster, potentially better alternative to the only other targeted drug on the market. The stock popped, but analysts say the real move hasn't happened yet.
Boehringer Ingelheim is teaming up with AI-biotech Immunai in a $15M deal to hunt for the next PD-1: unknown T-cell targets hiding across cancer and autoimmune disease. It's a small bet that could reshape how we think about immune checkpoints.
Pharma and biotech M&A has already topped $100 billion by mid-2026, with analysts projecting the biggest dealmaking year since 2019. Behind the frenzy: a massive patent cliff and two therapeutic areas every company wants to own.
Lantheus' cancer imaging agent had flawless clinical data and a clean safety profile. The FDA rejected it anyway, and the reason has nothing to do with science. It's a cautionary tale about the hidden risk that keeps torpedoing biotech approvals.
Biogen closed its $5.6 billion Apellis acquisition and almost immediately gutted the biotech's research pipeline, keeping only two approved drugs. It's a playbook Big Pharma has run for decades, and the cost isn't always measured in dollars.
Gilead is spending up to $5 billion to acquire Tubulis, a German ADC startup that went from a Munich university lab to biotech's hottest takeover target in just seven years. The deal reveals how antibody-drug conjugates have become pharma's most competitive M&A battleground.
The Trump administration threatened 100% tariffs on imported brand-name drugs, and 16 pharma giants blinked. The deals they struck could reshape how America prices medicine, but Wall Street thinks the whole thing might be a giant nothingburger.
A daily pill nearly doubled survival in metastatic pancreatic cancer, turning ASCO's toughest crowd into a 42-second standing ovation. After 40 years of calling KRAS "undruggable," the lock just got picked.
Columbia scientists used next-gen CRISPR base editing to fix disease mutations in human embryos with unprecedented precision, but persistent errors and a deepening ethics war over "designer babies" mean the hardest questions are just getting started.
Gilead paid $45 million for a cancer drug that hasn't been tested in a single patient. The preclinical molecular glue degrader deal with Kymera is small potatoes compared to Gilead's $13B+ oncology shopping spree, but the strategic signal about where pharma is headed is anything but small.
Novartis just agreed to pay up to $1.9 billion to a one-year-old spinout with zero clinical data. The catch: Antares Therapeutics might hold the key to drugging cancer targets that have stumped the entire industry for decades.
Moderna just entered the in vivo CAR-T race with a plan to reprogram your immune cells using a simple injection. If it works, it could turn autoimmune disease treatment from a million-dollar ordeal into something your local clinic could offer.
UCB is spending up to $1.15 billion on Neurona Therapeutics and its lab-grown brain cell therapy for drug-resistant epilepsy. The early clinical data is stunning, but the real test is just getting started.
For the first time ever, a drug has been approved specifically to slow disability in progressive MS patients who don't have relapses. Sanofi's Cenrifki just rewrote the treatment playbook for hundreds of thousands of patients who had zero options, but a liver safety signal already killed its chances in the US.
Insilico Medicine's rentosertib, a drug designed entirely by AI, just showed actual lung function improvement in an IPF trial where lungs are only supposed to get worse. It's the strongest proof yet that AI-driven drug discovery can produce real results in humans.
The FDA just spelled out exactly how CRISPR, base editing, and prime editing companies need to prove their therapies aren't making unintended changes to the genome. The new draft guidance on next-generation sequencing could reshape every gene editing IND filing from here on out.
Intellia's single-dose CRISPR therapy slashed hereditary angioedema attacks by 87% in a pivotal Phase 3 trial, with 62% of patients going completely attack-free. One injection that permanently edits your DNA while it's still inside you: the future of gene editing just got very real.
Merck KGaA is paying $11.3 billion in cash for Bio-Techne, a lab tools company most people outside biotech have never heard of. The deal reveals a quiet arms race among life science giants racing to control the picks and shovels of drug discovery.
Join thousands of biotech professionals who start their day with our free, daily briefing.